The offering was managed by TD Cowen as the lead book-running manager, with support from Guggenheim Securities, BTIG, and Craig-Hallum. This capital injection follows a registration statement effective since August 2025. The company intends to utilize the funds to further its mission of expanding access to data-driven medicine through its proprietary SOPHiA DDM platform.

Despite the global nature of the firm’s operations, the company clarified that these securities are not being offered or marketed in Switzerland under the Swiss Financial Services Act. No application for listing on the SIX Swiss Exchange has been made, and the offering remains strictly confined to jurisdictions where registration requirements are met.